Project Optimus: Drug Development Expertise Fits New FDA Guidance Targeting Cancer Therapeutics

Drug Development Expertise Fits New FDA Guidance Targeting Cancer Therapeutics 

Cancer therapeutics present a challenge to the pharmaceutical industry. Navigating this challenge requires technical expertise and modern drug development tools. Examples of these tools include modeling and simulation. A new FDA guidance for industry intends to upgrade the drug development process for human oncology drugs and biological products.

The new FDA guidance was inspired by Project Optimus. The guidance proposes that the future of cancer therapeutics will rely on finding the safest and most efficacious product. 

Project Optimus originated from the FDA's Oncology Center of Excellence (OCE), led by Richard Pazdur, MD. The project focuses on improving the important phases of translational development. 

Project Optimus targets the preclinical stages of drug development, focusing on optimal dosing, as well as the clinical path to product approval. These activities will be driven under this new FDA guidance that emphasizes dose optimization and selection of targeted therapeutics. 

The guidance intends to shift the industry away from traditional chemotherapy approaches. These approaches were based on selecting a maximum tolerated dose (MTD). Over time, this standard approach has resulted in safety concerns. 

The new proposed standards will allow for superior analysis of drug activity, safety, and tolerability data. By building stronger relationships between the FDA and drug developers, this change ensures the highest possibility of therapeutic success. 

Early communication is now highly encouraged before submitting a drug application for approval. Amador is highly experienced and ready to support communications with regulatory agencies early in drug development. This will allow these agencies to review development plans for new therapeutics and offer expedited feedback. This collaborative submission effort will require strategic, evidence-based planning that Amador’s highly experienced Regulatory Affairs team is fit to lead. 

The Impact of the New FDA Guidance on the Future of Cancer Therapeutics 

It is anticipated that careful dose optimization and selection will be at the forefront of new quality cancer therapeutics. Modern pharmaceuticals and biologics are expected to have a better chance of approval. This could lead to improved patient outcomes. The new FDA guidance will improve the drug development process to reduce costs with better patient access to affordable therapeutics. 

The field of cancer therapeutics relies on many scientific disciplines to reach healthcare goals. It will continue to do so while introducing new processes. 

Forecasted improvements will include the strategic use of fit-for-purpose biomarkers and improved trial designs. Adaptive trial design, which allows flexibility during a trial, is expected to be essential for these advancements. Dose-finding trials will be directed to use real-world strategy to achieve optimal analysis in exposure-response and safety profiling. 

Amador's translational experts are highly skilled. They use computational modeling and simulation tools to evaluate and select optimized trial dosing. This is essential for adapting to rapidly changing industry standards. 

Modeling and Simulation for Optimal Dose Selection 

Quantitative clinical pharmacology tools are essential for modern early-stage drug development. They play an important role in achieving the objectives of Project Optimus. 

These tools use computational modeling. This modeling relies on age, body weight, and other parameters. 

It generates expected scenarios under calibrated specified conditions. By simulating various dose regimens, potential outcomes will be predicted. This can then be leveraged to improve future trial designs, dose selection, and dose optimization. Various modeling software packages, showcasing these tools, are accessible to perform these simulations. 

Amador has extensive experience with PK/PD models. These models can assess a variety of doses, which can aid in the early FDA submission process. PK/PD models explore the relationship between drug concentration and drug effect over time. Variations of the model substitute a steady-state parameter for time. 

Population pharmacokinetic (PopPK) models are also used to explore variability between drug concentrations across specific populations to appropriately determine therapeutic safety and efficacy. Amador recently improved its PopPK model tools to characterize the PK and exposure-response of the monoclonal antibody (mAb) cemiplimab in patients with recurrent or metastatic cervical cancer (R/M CC). 

External validation of the model showed that predictions were consistent with actual PK data. The results from Amador’s updated model will support the selection of the optimal dose to treat this type of cancer. Amador aligns these tools with expertise in clinical trial design to thoroughly evaluate antitumor activity, safety, efficacy, tolerability, and other pertinent variables. 

Improved Trial Designs for Studies Pre-Application 

The new FDA guidance emphasizes trial design improvement in the pre-market application to mimic clinical trials that evaluate multiple doses. Recommendations include expanding the number of patients in dose-finding trials, including a control arm, and using adaptive trial design randomization. These changes can reduce the time required to find the optimal dose, considering safety and tolerability. 

Amador’s Clinical Pharmacology and Clinical Research teams will assist in developing projects which align with these recommendations. These teams understand how to lead studies which use adaptive trial design and randomized doses in parallel dose-response trials. This approach provides a smoother transition into clinical trials and increases patient clinical benefit. 

Updated Safety and Tolerability Expectations 

To achieve optimal clinical benefit, patients must have access to oncology products that are safe and tolerable. The FDA recommends assessing safety and tolerability during multiple-dose trials. This practice means considering factors that impact safety, including adverse reactions, determination of dose changes, and the duration of exposure. 

Amador is supporting this new thinking by integrating novel bioanalytical approaches. This includes immunogenicity profiling and toxicokinetic analysis. This will allow Amador to optimally maximize safety and fine-tune tolerability during the pivotal stages of clinical development. 

Future Direction 

Meeting proposed high-quality standards for dose selection and optimization can help reduce toxicity and harm. This will improve cancer patients' quality of life and increase their chances of survival. 

Traditional approaches did not extensively investigate safety and tolerability in the past. This new guidance sets the foundation for determining optimal doses for cancer therapeutics under realistic conditions that favor success. This new paradigm shift is poised to support a faster review and approval path in cancer therapeutics. 

Amador is committed in developing rapid and effective strategies to identify optimal doses for therapeutic products which target cancer disease and improve patient’s lives.  

Want to learn more?